After growing its Xenium In Situ single-cell spatial imaging platform into its third successful technology family last year, 10x Genomics has no plans for launching a fourth platform in 2024—but will ...

10x Genomics is up 7.5% since the beginning of the year, and at $15.26 per share, it is trading close to its 52-week high of $16.47 from December 2024. Investors who bought $1,000 worth of 10x ...

PLEASANTON, Calif., Dec. 29, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 6.3% in the morning session after Citigroup downgraded the stock to Neutral from Buy. The analyst firm adjusted its rating on the life science ...

SAN DIEGO--(BUSINESS WIRE)--Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with 10x Genomics, a life sciences leader focused on ...

July 11 (Reuters) - A federal judge in Delaware said on Monday that 10x Genomics (TXG.O), opens new tab and Harvard University must face antitrust counterclaims over their licensing practices in two ...

10x Genomics has been on my Compounding Healthcare “Bio Boom” speculative portfolio watch list since its IPO back in 2019. I believe 10x Genomics is becoming an entrenched name. After performing some ...

Forbes contributors publish independent expert analyses and insights. Steven covers accessibility and assistive technologies. Aug 07, 2023, 01:54pm EDT Aug 07, 2023, 03:58pm EDT This article is more ...

PLEASANTON — 10x Genomics has marked a new phase in its remarkable expansion by opening a modern office building that has just sprouted in Pleasanton, coupled with plans for even more growth at its ...

PLEASANTON — 10x Genomics has crafted plans for a major expansion of its Pleasanton operations through the purchase of a big property that it will develop as a modern campus, the biotech company said ...